Michael Pisetsky Sells 3,134 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,134 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $16.71, for a total transaction of $52,369.14. Following the sale, the senior vice president directly owned 277,375 shares in the company, valued at approximately $4,634,936.25. The trade was a 1.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Price Performance

Shares of NASDAQ:SIBN traded up $0.57 during trading on Monday, hitting $17.68. 414,032 shares of the company were exchanged, compared to its average volume of 641,629. SiBone has a 1-year low of $11.48 and a 1-year high of $21.89. The company has a market capitalization of $784.11 million, a P/E ratio of -45.33 and a beta of 0.67. The company has a quick ratio of 8.34, a current ratio of 9.99 and a debt-to-equity ratio of 0.20. The business’s 50 day moving average is $14.70 and its 200-day moving average is $15.50.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.07. The company had revenue of $52.59 million for the quarter, compared to the consensus estimate of $51.16 million. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%. Equities analysts forecast that SiBone will post -0.44 earnings per share for the current year.

Institutional Trading of SiBone

Several institutional investors have recently added to or reduced their stakes in the stock. ANTIPODES PARTNERS Ltd bought a new position in SiBone during the 4th quarter worth approximately $29,000. Versant Capital Management Inc boosted its stake in shares of SiBone by 102.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after purchasing an additional 887 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of SiBone by 98.5% in the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after purchasing an additional 736 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of SiBone by 64,700.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock worth $38,000 after buying an additional 1,941 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of SiBone during the fourth quarter worth $53,000. 98.11% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on SIBN shares. Truist Financial reiterated a “buy” rating and set a $18.00 target price (down from $20.00) on shares of SiBone in a research report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SiBone in a research note on Thursday. Wall Street Zen lowered shares of SiBone from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Finally, TD Cowen decreased their price objective on SiBone from $22.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, SiBone has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.